Finnhub•2026-04-20
CVRx Announces Nomination of Michael Dale for Election to the Board of DirectorsCVRX — CVRx Inc
NASDAQ · Health Care · Health Care
$7.98-5.56%Market cap237.07M
- Latest Close
- $7.98
- 30-Day Move
- -5.6%
- Market Cap
- $237M
- Shares Outstanding
- 26,310,000
- P/B Ratio
- 4.73
- ROE
- -135.6%
Analyst consensus: Buy · 13 analysts
NASDAQ:CVRXHealth Care / Health CareDelayed public snapshot
CVRx Inc
A read-only Alphactor snapshot forCVRx Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-22
Topline snapshot
Latest Close
$7.98
30-Day Move
-5.6%
Market Cap
$237M
Shares Outstanding
26,310,000
P/B Ratio
4.73
ROE
-135.6%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$7.98
-5.6%last 90 delayed daily bars
Market cap$237M
90D High
$9.84
90D Low
$4.37
Avg Volume
322,943
What stands out
Gross margin is running at 85.3%, which gives a quick read on operating quality before you open the full model.
Net margin is -94.1%, useful for comparing CVRX against peers in Health Care.
CVRX is down 5.6% over the last 30 trading days shown on this page.
Latest operating income is $-51M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$11.72
Rule of 40
-61.5%
Dark Pool Short %
45.5%
Fundamentals snapshot
Latest Close
$7.98
30-Day Move
-5.6%
Market Cap
$237M
Shares Outstanding
26,310,000
P/B Ratio
4.73
ROE
-135.6%
ROA
-50.9%
Gross Margin
85.3%
Operating Margin
-90.5%
Net Margin
-94.1%
Debt / Equity
1.26
Current Ratio
7.63
Latest Revenue
$57M
Financial statement snapshot
Revenue
$57M
Gross Profit
$48M
Operating Income
$-51M
Net Income
$-53M
Gross Margin
8533.0%
Net Margin
-9410.0%
Current Ratio
7.63
Debt / Equity
1.26
Valuation snapshot
Fair Value
$11.72
Upside / Downside
+46.9%
Signal
Undervalued
Implied Growth
--
EV/Rev
$11.72
Growth Assumption
36.1%
Discount Rate
10.9%
Terminal Growth
2.0%
Base FCF
--
Valuation spread
Current Price
$7.98
Composite Fair Value
$11.72
EV/Rev
$11.72
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative FCF — company is cash-flow negative. Reverse DCF requires positive cash flows.
Quality snapshot
Altman Z
-5.78
Distress
Piotroski
3
Weak (0-3)
Cash Conversion
0.75x
Rule of 40
-61.5%
Concerning
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $22M | $-43M | $-41M | $-43M |
| 2023-12-31 | $39M | $-43M | $-41M | $-40M |
| 2024-12-31 | $51M | $-59M | $-60M | $-41M |
| 2025-12-31 | $57M | $-51M | $-53M | $-41M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
After signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$1M
Sell Value
$987,617.05
Buys
9
Sells
13
Buy Value
$1M
Sell Value
$987,617.05
Buy/Sell Ratio
0.69x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-02 | Adamson Philip B. | Sell | 1,262 | $7.90 |
| 2026-03-02 | Morrison Gregory | A | 154,500 | $0.00 |
| 2026-03-02 | Morrison Gregory | A | 34,000 | $0.00 |
| 2026-03-02 | John Robert Allen | Sell | 3,964 | $7.90 |
| 2026-03-02 | VERRASTRO PAUL | Sell | 1,284 | $7.90 |
| 2026-03-02 | OASHEIM JARED | Sell | 1,744 | $7.90 |
| 2026-03-02 | Hykes Kevin | Sell | 7,763 | $7.90 |
| 2026-02-27 | Adamson Philip B. | A | 62,000 | $0.00 |
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 684,121 | 0.03% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | 384,404 | 0.01% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 185,817 | 0.01% | 2025-12-31 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 154,347 | 0.01% | 2026-01-31 |
| iShares Trust-iShares Russell 2000 Growth ETF | 141,035 | 0.01% | 2026-02-28 |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 95,548 | 0.00% | 2026-02-28 |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 78,417 | 0.00% | 2025-11-30 |
| Bridgeway Funds, Inc.-Ultra-Small Company Market Fund | 49,600 | 0.00% | 2025-12-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
Two Sigma Advisers
Filed 2026-02-17
--
--
BlackRock
Filed 2024-05-10
$14M
--
Vanguard Group
Filed 2025-05-09
$12M
+10.7%
Geode Capital Management
Filed 2025-11-12
$3M
+5.9%
Citadel Advisors
Filed 2025-05-15
$3M
--
Dark-pool activity snapshot
Analyst consensus?
Rating(?)
4
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
13
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.